NASDAQ: UBXUnity Biotechnology Inc Stock
$1.44-0.01 (-0.69%)
Updated Sep 9, 2024
UBX Price
$1.44
Fair Value Price
-$0.49
Market Cap
$24.26M
52 Week Low
$1.22
52 Week High
$2.60
P/E
-0.83x
P/B
1.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.71
Operating Cash Flow
-$24M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UBX Overview
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UBX ($1.44) is overvalued by 396.01% relative to our estimate of its Fair Value price of -$0.49 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UBX ($1.44) is not significantly undervalued (396.01%) relative to our estimate of its Fair Value price of -$0.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UBX due diligence checks available for Premium users.
Be the first to know about important UBX news, forecast changes, insider trades & much more!
UBX News
Valuation
UBX fair value
Fair Value of UBX stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
-$0.49
Undervalued by
396.01%
UBX ($1.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UBX ($1.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.83x
Industry
-98.37x
Market
24.05x
UBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.23x
Industry
6.32x
UBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
UBX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$53.5M
Liabilities
$33.8M
Debt to equity
1.71
UBX's short-term assets ($35.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UBX's short-term assets ($35.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UBX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
UBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$4.7M
Financing
$68.0k
UBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UBX vs Biotech Stocks
Unity Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.